Abnormal expression of ANRIL facilitates the incidence of a range of atherosclerosis-related impairments including vascular endothelial injury, deteriorations in VSMCs, mononuclear cell adhesion/proliferation imbalance, glycolipid metabolism disorder, DNA damage, and competing endogenous RNAs [3]. This evidence concerns the gene CDKN2B-AS1 and atherosclerosis.